Health

JinMed's Nanobathing Products Receive Multiple Patent Certifications and Sign Directed Procurement Agreement with Shanghai Zhongjin HongKang Medical Technology

CHANGZHOU, China, Aug. 3, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("the Company" or "JinMed") (NASDAQ: ZJYL) which is the world's leading provider of rehabilitation equipment. Currently, the Company's nanobathing products have been granted an invention patent and four utility model pa...

2023-08-03 17:13 1097

MANA Develops Novel "Drycell" Microdroplets to Make Handling Single Cell Easier

TSUKUBA, Japan, Aug. 3, 2023 /PRNewswire/ -- Scientists at the Research Center for Materials Nanoarchitectonics (MANA) have developed micrometer-sized "liquid marbles" that can encapsulate single to several living cells, thereby aiding single-cell studies. To analyze individual cells, the desire...

2023-08-03 16:00 1047

ESMO 2023 | Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress

SUZHOU, China, and ROCKVILLE, Md., Aug. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it is going to release results from two clinic...

2023-08-03 11:43 1259

SK Biopharmaceuticals Assembles 'Board of Prominent Experts' to Boost Growth, Innovation

Renowned oncologist Yung-Jue Bang, M.D., Ph.D., chairs the distinguished 5-member Scientific Advisory Board to further advance SK Biopharmaceuticals as a global big biotech SEOUL, South Korea, Aug. 2, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation o...

2023-08-03 07:30 1360

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting

SYDNEY, Aug. 2, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough c...

2023-08-03 07:00 1188

U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with Glioblastoma Harboring BRAF V600 Mutation

SAN DIEGO and SHANGHAI, Aug. 2, 2023 /PRNewswire/ -- ABM Therapeutics (ABM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed by the company, for the treatment of patients with g...

2023-08-03 00:00 1222

Atantares has Completed Two Rounds of RMB100 Million Financing, and the Pre-A Round is led by Asia Green Fund

BEIJING, Aug. 2, 2023 /PRNewswire/ -- Recently, Atantares announced the completion of Pre-A and Pre-A+ financing all aroundRMB100 million. The Pre-A round is led by Asia Green Fund, followed by Fosun Health Capital and existing investors Frees Fund, Qiming Venture Partners, Next Capital, and NeuX...

2023-08-02 14:56 1659

AmCham South China Study - Business Confidence in China Rising, Increases in Investment Plans Observed

GUANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- The American Chamber of Commerce inSouth China (AmCham South China)  released its 2023 Mid-Year Report on Impact of COVID Policy Change. The study shows slow but steady improvement in business sentiment, investments, and activities in the first half ...

2023-08-02 09:00 1265

Lunit Presents Groundbreaking Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

- Collaborative study with NCCHE shows that AI analysis of HER2 expression and the tumor microenvironment is linked to treatment response of Pertuzumab+Trastuzumab in colorectal cancer SEOUL, South Korea, Aug. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered soluti...

2023-08-01 21:00 1610

Terumo Blood and Cell Technologies' Reveos® Automated Whole Blood Processing System Cleared by FDA for U.S. Commercial Use

Reveos is positioned to help U.S. blood centers supplement the platelet supply, reduce labor and costs, and improve overall operational efficiency LAKEWOOD, Colo., Aug. 1, 2023 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT) announces U.S. Food and Drug Administration (FDA) clear...

2023-08-01 20:30 1459

NEW AMAZFIT BIP 5 GOES BIGGER AND SMARTER WITH AN EXTRA-LARGE SCREEN, 70+ DOWNLOADABLE APPS AND GAMES, AND MORE

MILPITAS, Calif., Aug. 1, 2023 /PRNewswire/ -- Amazfit , a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has today made the new Amazfit Bip 5 globally available. Encouraging users to "Go Bigger, Go Smarter", the Ama...

2023-08-01 20:00 1544

Peijia Medical Announces First Chinese Patient Implanted with TaurusTrio™ Transcatheter Aortic Valve Replacement System

SUZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced onJuly 31, 2023 that the first Chinese patient of the multi-center ...

2023-08-01 20:00 2226

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

The Company now has exclusive rights to a US and Chinese patent. SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore -based biopharmaceutical company focused on harnessing its proprietary technologies ...

2023-08-01 19:00 1368

Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA

HANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...

2023-08-01 17:08 1069

Hybribio showcased cutting-edge cervical cancer HPV diagnostic solutions at ADLM 2023

ANAHEIM, Calif., July 31, 2023 /PRNewswire/ -- Hybribio (300639.SZ) exhibited live at the 75th ADLM (former AACC) Annual Scientific Meeting & Clinical Lab Expo,July 25-27, at Anaheim Convention Center, California, USA. This event attracted 958 exhibitors and over 70,000 attendees worldwide from d...

2023-08-01 01:00 1723

Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC

* Introduced syndromic quantitative PCR assays and a fully automated molecular diagnostic testing system, STARlet AIOS™ * Conducted symposium sessions on the usefulness of PCR testing in diagnosing gastrointestinal diseases * Participated in a presentation event for major Korean in-vitro dia...

2023-08-01 00:00 1353

Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together

BOSTON, July 31, 2023 /PRNewswire/ -- On July 25, 2023, Fosun Health Capital established by Fosun Pharma (stock code:600196.SH), reached a strategic partnership with Medicilon (stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) (jointly invested by the innovation drug research fund of Fo...

2023-07-31 20:30 2138

Skincare Tech Brand AMIRO Receives QTL Certification from SGS to Strengthen R&D Efforts

SHENZHEN, China, July 31, 2023 /PRNewswire/ -- AMIRO ("the Company"), a leading beauty and skincare technology brand, is thrilled to announce that its research facility,AMIRO LAB, has successfully obtained the Qualified Testing Location (QTL) certification after a comprehensive audit conducted by...

2023-07-31 20:15 1514

WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022

* Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% * Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 27.9% * Net Profit Attributable to Owners of the Co...

2023-07-31 18:02 4004

111 to Announce Second Quarter 2023 Unaudited Financial Results on August 24, 2023 - Conference Call to Follow

SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial result...

2023-07-31 17:59 1573
1 ... 71727374757677 ... 273